Ditemukan 13 dokumen yang sesuai dengan query :: Simpan CSV
Penyakit HIV/AIDS merupakan masalah kesehatan di Indonesia. Masalah yang berkembang adalah karena angka morbiditas dan mortalitas yang masih tinggi, disebabkan antara lain karena keterlambatan mendapatkan pengobatan Anti Retroviral (ARV). Di Indonesia pengobatan ARV umumnya dimulai bila jumlah sel CD4 < 200 sel/mm 3 atau bila stadium klinis 3 atau 4. Informasi tentang pengaruh jumlah sel CD4 sebelum pengobatan ARV terhadap ketahanan hidup satu tahun pasien HIV/AIDS berdasarkan kelompok kategori 3 , 50- 3 dan > 200 sel/mm 3 , saat ini belum tersedia di Indonesia. Untuk mengetahuinya, maka dilakukan penelitian ini. Desain penelitian kohort retrospektif, dilakukan pengamatan terhadap kematian pada populasi dinamis selama satu tahun (366 hari), dari Januari 2005 hingga Januari 2010. Subjek penelitian 158 pasien HIV/AIDS berusia > 15 tahun, naïve dan mendapat regimen ARV lini pertama di RSPI Prof.DR.Sulianti Saroso pada tahun 2005-2010. Prosedur analisis ketahanan hidup menggunakan metode Kaplan-Meier (product limit), analisis bivariat dengan Log rank test (Mantel cox) dan analisis multivariat dengan cox regression / cox proportional hazard model. Penelitian ini mendapatkan probabilitas ketahanan hidup keseluruhan satu tahun pasien HIV/AIDS dengan pengobatan regimen ARV lini pertama adalah 0,86 (CI 95% 0,79-0,91). Incident rate kematian (Hazard rate) kelompok jumlah sel CD4 3 adalah 8/10.000 orang hari (29/100 orang tahun), kelompok jumlah sel CD4 50-3 adalah 3/10.000 orang hari (11/100 orang tahun) dan kelompok jumlah sel CD4 > 200 sel/mm 3 adalah 2/10.000 orang hari (7/100 orang tahun). Hazard Ratio(HR)-adjusted kelompok jumlah sel CD4 <50 sel/mm 3 terhadap kelompok jumlah sel CD4 > 200 sel/mm 3 adalah 3,4 (p= 0,058 ; CI 95% : 0,96-12,16), HR-adjusted kelompok jumlah sel CD4 50-3 terhadap kelompok jumlah CD4 > 200 sel/mm 3 adalah 1,7 (p= 0,48 ; CI 95% : 0,4-7.04). HR-adjusted pasien dengan TB 3,57 kali terhadap pasien tanpa TB (p=0,015 ; CI 95% : 1,27-9,99). Jumlah sel CD4 sebelum pengobatan ARV tidak mempunyai pengaruh secara statistik terhadap ketahanan hidup satu tahun pasien HIV/AIDS yang mendapat regimen ARV lini pertama. Namun penelitian mendapatkan penyakit Tuberkulosis (TB) mempunyai pengaruh secara statistik terhadap ketahanan hidup satu tahun pasien HIV/AIDS yang mendapat regimen ARV lini pertama. Kata kunci: HIV/AIDS, jumlah sel CD4, pengobatan ARV, ketahanan hidup satu tahun.
HIV/AIDS disease is one of public health concerns in Indonesia. The growing issues related to high morbidity and mortality rate. This is due to such as lately initiated of Antiretroviral (ARV) therapy. In Indonesia ARV therapy is begun when the CD4 cell counts dropped below 200 cell/mm 3 or if clinical stadium fall into 3 rd th or 4 . Nowadays in Indonesia, Information about the influenced of baseline CD4 cell count to one year survival among patient HIV/AIDS with first line ARV regimen therapy, base on strata 3 , 50- 3 and > 200 cell/mm 3 was not available, therefore this research will be conducted. Study design was retrospective cohort, with one year (366 days) duration of observation to death, in dynamic population from January 2005 to January 2010. The subjects of study were 158 HIV/AIDS patients, with inclusion criteria: > 15 years old, naïve, and were treated by first line ARV regimen at RSPI Prof.DR. Sulianti Saroso in year 2005-2010. The procedures of survival analysis used Kaplan-Meier method (product limit), and Log rank test (Mantel cox) for bivariate analysis and cox regression / cox proportional hazard model for multivariat analysis. The overall of one year survival probability in HIV/AIDS patients with first line ARV regimen therapy was 0,86 (CI 95% 0,79-0,91). Incident rate of death (Hazard rate) in CD4 3 group was 8/10.000 persons days (29/100 persons years), in CD4 50-3 group was 3/10.000 persons days (11/100 persons years) and in CD4 > 200 cell/mm 3 group was 2/10.000 persons days (7/100 persons years). The Hazard Ratio(HR)-adjusted CD4 <50 cell/mm 3 patients compared to CD4 > 200 cell/mm 3 patients was 3,4 (p= 0,058 ; CI 95% : 0,96-12,16), the HR-adjusted CD4 50-3 patients compared to CD4 > 200 cell/mm 3 patients was 1,7 (p= 0,479 ; CI 95% : 0,4-7.04). HR- adjusted tuberculosis patients was 3,57 time more risk to death than patients without tuberculosis (p=0,015 ; CI 95% : 1,27-9,99). This study found that the baseline CD4 cell counts have not significant statistical associated to one year survival of HIV/AIDS patients with first line ARV regimen therapy, after has controlled to other independent variables. But this study found that tuberculosis has significant statistical association to one year survival of HIV/AIDS patients who received first line ARV regimen therapy. Keywords: HIV/AIDS, CD4 cell counts, treatment ARV, one year survival.
ABSTRAK Retensi ARV Pada Pasien HIV Berdasarkan CD4 Awal Terapi ARV di RSPI Prof. Dr. Sulianti Saroso Jakarta Dari Tahun 2011 – 2014 Musa Rapang Perbedaan tingkatan imunodefesiensi memberikan kondisi klinis yang berbeda. Dampak perbedaan imunodefesiensi akan diperoleh retensi ARV yang berbeda pada tingkat imunodefesiensi berat dan sedang. Pasien dengan sistem imun yang baik (CD4 tinggi) kemungkinan akan memiliki retensi yang rendah. Tujuan penelitian ini adalah untuk melihat apakah perbedaan retensi ARV pada pasien HIV AIDS berdasarkan CD4 saat terapi ARV di RSPI Sulianti Saroso Jakarta. Penelitian ini menggunakan desain kohort retrospektif menggunakan 223 sampel yang diambil dari data rekam medik rumah sakit dari tahun 2011 – 2014 dengan waktu pengamatan selama satu tahun. Pasien yang retensi ada 70.85% dengan insident rate lost to follow up 2.9 per 100 orang bulan. Retensi ARV pada pasien dengan CD4 200-350 sel/mm lebih baik dengan HRadj lost to follow up sebesar 0.27 (CI 95% : 0.1 – 0.8) kali lebih rendah dibandingkan pasien dengan CD4 <200 sel/mm 3 . Selain itu pasien memiliki CD4 200350 sel/mm 3 pada stadium awal memiliki risiko lost to follow up yang lebih tinggi dengan HRadj 1.10 (CI 95% : 0.5 – 2.4) kali lebih tinggi dibandingkan dengan pasien yang memiliki CD4 < 200 sel/mm 3 pada stadium awal. Perlu dilakukan monitoring klinis, eduksi dan dukungan kepada pasien tentang manfaat ARV khususnya pada pasien dengan CD4 <200 sel/mm 3 . Kata kunci : Retensi ARV, CD4 Awal, lost to follow up
ABSTRACT ARV Retention HIV Patients Based On Early CD4 Therapy In Hospital Infection Disease of Prof. Dr. Sulianti Saroso Jakarta From Years 2011 - 2014 Musa Rapang The difference in the level of imunodefesiensi provide different clinical conditions. The impact will be acquired at different ARV retention rate of severe and moderate imunodefesiensi. HIV Patients with a good immune system (CD4 high) possibility have poor retention on antiretroviral drugs, so that the patient will tend to experience a lost to follow up. The purpose of this study was to see whether the difference in retention of antiretroviral drugs in HIV-AIDS patients by CD4 time ARV therapy in hospital Prof. Dr. Sulianti Saroso Jakarta. This research using retrospective cohort design using 223 samples taken from hospital medical records from the years 20112014 with the observation time for one year. The number of patients there was 70.85% retention with number incidents of lost to follow-up rate of 2.9 per 100 person-months. Retention ARV based on baseline CD4 200-350 cells / mm better with HRadj of lost to follow-up at 0.27 (CI 95% :0.1 – 0.8) times slower compared to patients with CD4 <200 cells / mm 3 in the early stages having lost to follow-up speed faster with HRadj 1.10 (CI 95% :0.5 – 2.4) times faster compared with patients with CD4 <200 cells/mm 3 . In addition patients had CD4 200-350 cells / mm 3 early stage. Needed to monitoring, education and supporting to patient for benfit to use ARV especially to patient with CD4 <200 cells/mm 3 . Keywords: Retention ARV, CD4 Earlier, Lost to follow up
Infeksi HIV pada tubuh bertindak sebagai stresor yang akan menimbulkan permasalahan bagi individu yang terinfeksi di ataranya masalah fisik, psikologis dan psikososialnya. Permasalahan fisik terkait dengan perjalanan penyakit dan komplikasi sistem saraf pusat, mulai dari munculnya gejala penyakit, turunnya sistem kekebalan tubuh. Masalah psikosial dan psikologis yang dialami oleh penderita HIV diantaranya adalah munculnya stigma dan diskriminasi baik didalam keluarga maupun di masyarakat.
HIV infection in the body act as stressors that will cause problems for individuals infected among physical, psychological and psychosocial. Physical problems related to the course of the disease and complications of the central nervous system, starting from the symptoms appearance of the disease, the decline of the immune system. Psychosocial and psychological problems experienced by HIV sufferers include the emergence of stigma and discrimination within the family and in society.
IntroductionDramatically, Anti-Retroviral drug Therapy (ART) has reduced morbidity andmortality of People Living with HIV/AIDS (PLWHA). However, adherence toantiretroviral therapy has become a challenge because this therapy must beendured for a lifetime. Adherence to antiretroviral therapy is one of the factorsthat determine the success of treatment. Poor adherence to ARV therapy inIndonesia is arround 23-55%. The objective of this study was to determine theinfluence of medication non-adherence to the 3-years survival of patients withHIV/AIDS.MethodsThis study used a retrospective cohort design at RSPI Prof. Dr. Sulianti Saroso in2010-2012.ResultsThe cumulative survival probability of patients with HIV/AIDS at RSPI Prof. dr.Sulianti Saroso in the second year (24th month) was 95.6% and the third year (inthe 36th) was 91%. Multivariate analysis with Cox regression showed the factorsthat affected the 3-years survival of patients with HIV/AIDS are non-adherence toART, after controlled by initial CD4 count (aHR = 7.608; 95% CI: 1.664 to34.790), and non-compliance appointments, after controlled by opportunisticinfection, age and initial CD4 count (aHR = 2.456; 95% CI: 0.802 to 7.518).Among patient non-adherence to ART, non-compliance appointments affected the3-years survival of patients with HIV/AIDS, after controlled by initial CD4 count,sex, CPT, modes of HIV transmission, WHO clinical stage, opportunisticinfection, and age (aHR = 4.517 ; 95%CI : 0.729-27.987).DiscussionsNonadherence to ART may caused a failure of the suppression on HIV viral, thusincrease the possibility of HIV virus mutations that can lead to drug-resistant andultimately increase the risk of death. Poor adherence to appointments of takingdrugs in the first year also assumed the poor adherence of the next assignment totake drugs in the further, and show disobedience to ART, so it will increase therisk of death.RecomendationMonitoring coverage of medication adherence of patients with HIV/AIDS in aregular basis as the early warning on the risk of death among patients withHIV/AIDS.Keyword : non-adherence to ART, appointment keeping, retrospective cohort
